for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Remdesivir not associated with kidney problems - EU drugs regulator

Feb 12 (Reuters) - A safety panel at the European Medicines Agency said on Friday there was no evidence that Gilead’s COVID-19 drug remdesivir caused kidney problems in some patients.

Separately, the pharmacovigilance risk assessment committee said it was not yet clear if there was a causal association between remdesivir and reports of sinus bradycardia in patients, and started a new assessment for the same.

Reporting by Tanishaa Nadkar in Bengaluru; Editing by Shinjini Ganguli

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up